Annovis Bio, Inc. cotiza a 1.15 USD y tiene una capitalización bursátil de $49M. Datos fundamentales de la SEC EDGAR con hasta 20 años de histórico, insiders, institucionales y valoración DCF.Más empresas del sector Salud
Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration in the United States. The company's lead product candidate is Buntanetap, which is in phase 3 to treat alzheimer's disease, as well as in open-label phase 3 to treat parkinson's disease. It also develops ANVS405, which …
| Periodo | 2026-08 | 2026-05 | 2026-03 | 2025-11 |
|---|---|---|---|---|
| Real | $-0.40 | $-0.63 | $-0.39 | $-0.37 |
| Estimado | $-0.46 | $-0.35 | $-0.30 | $-0.37 |
| Sorpresa | +13.0% | -80.0% | -30.0% | +0.0% |
| Métrica | ANVS | Mediana Sector | Δ |
|---|---|---|---|
| Gross Margin | — | 57.0% | — |
| Operating Margin | — | -38.6% | — |
| Net Margin | — | -33.6% | — |
| FCF Margin | — | -13.9% | — |
| ROE | -171.2% | -40.4% | -130.8% |
| ROA | -136.9% | -32.0% | -104.9% |
| Current Ratio | — | 2.84 | — |
| Debt / Equity | — | 0.28 | — |